Approach to medical therapy in perianal Crohn's disease.

The study identified a numerical difference in fistula closure rates in favor of vedolizumab at week 14 (28% vs 11%) and 52 (31% vs 11%), although these did not reach statistical significance, and no difference was noted between maintenance therapy given every 4 wk or 8 wk.

also in 111,027 other papers